Many patients with type 2 diabetes fail to achieve adequate glucose control despite escalation of treatment and combinations of multiple therapies including insulin. Patients with long-standing type 2 diabetes often suffer from the combination of severe insulin deficiency in addition to insulin resistance, thereby requiring high doses of insulin delivered in multiple injections to attain adequate glycemic control. Insulin-pump therapy was first introduced in the 1970s as an approach to mimic physiological insulin delivery and attain normal glucose in patients with type 1 diabetes. The recent years have seen an increase in the use of this technology for patients with type 2 diabetes. This article summarizes the clinical studies evaluating insulin pump use in patients with type 2 diabetes and discusses the benefits and shortcomings of pump therapy in this population.
Introduction
Diabetes is one of the most common chronic diseases in the world estimated to affect 415 million individuals worldwide [1] . Individuals with diabetes suffer from high morbidity and mortality rates because of complications which may be to some extent prevented with tight glycemic control. The importance of tight glycemic control in minimizing microvascular complications has been well established in type 1 diabetes (T1D) [2, 3] . The United Kingdom Prospective Diabetes Study established the benefit of tight glycemic control in patients with type 2 diabetes (T2D) demonstrating a similar reduction in the risk of microvascular complications to that which had been demonstrated in patients with T1D [4] . Glycemic control as close to the normal range as safely possible, with an HbA 1c level <7% for most patients, is now the goal for patients with T2D. However, target HbA 1c levels in patients with T2D should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. The HbA 1c goal should also be set somewhat higher for older patients and those with a limited life expectancy [5] .
Treatment of patients with T2D includes education, evaluation for microvascular and macrovascular complications, normalization of glycemia, minimization of cardiovascular and other long-term risk factors, and avoidance of drugs that can aggravate abnormalities of insulin or lipid metabolism. Weight reduction, diet, and oral medications can all be used to improve glycemic control, although the majority of patients with T2D fail to maintain glycemic targets in the long run even after a successful initial response to therapy. Insulin reserve declines with the natural progression of T2D, necessitating exogenous insulin therapy in long standing disease in many of the patients [6, 7] .
Insulin replacement therapy has undergone several major developments since its inception in the early 20th century, allowing for treatment approaches that seek to mimic normal insulin physiology and achieve tight glycemic control.
In patients with T2D, insulin is commonly provided in three ways:
(1) As a basal supplement using intermediate-or long-acting preparations to suppress hepatic glucose production and maintain near normoglycemia in the fasting state, (2) as a premixed combination of intermediateacting with short-acting or rapid-acting insulin, (3) as a basal -bolus regimen or 'intensive insulin therapy', similar to treatment in T1D. This regimen separates basal insulin delivery (given as one to two daily injections of intermediate-or long-acting insulin) with superimposed doses of short-or rapid-acting insulins before meals to limit postprandial glycemic excursions. A regimen of basal-plus insulin is often considered as an intermediary, adding a single prandial injection in addition to basal insulin prior the meal with the highest post-prandial excursion. A full basal-bolus regimen may be achieved by multiple daily injections of insulin (MDI) or by continuous subcutaneous insulin infusion (CSII) delivered by an insulin pump. The addition of basal insulin to other anti-diabetic therapies improves glycemic control and achieves the target HbA 1c level in over 50-60% of patients [5, 6] . Treatment intensification with prandial insulin achieves glycemic targets in >70% of patients [7] . Still, at least one quarter of patients with T2DM who receive insulin injections have poor glycemic control (HbA 1c ≥9%) (NHANES 1999 (NHANES -2004 [8] . Full compliance with insulin therapy regimens remains challenging, and injection anxiety, quality of life disruption and discomfort are all well-documented obstacles [9] . For insulin-requiring T2D patients, an insulin pump is an available alternative to the MDI regimen.
Insulin-pump therapy was first introduced in the 1970s as an approach to achieve normal glucose in patients with T1D by mimicking the normal insulin secretion patterns that are present in persons without diabetes. A portable pump infuses rapid-acting insulin at a slow basal rate, 24 h a day, through a fine cannula implanted in the subcutaneous tissue, with patient-activated insulin boosts (boluses) administered at mealtimes. With insulin pumps in current use, the basal rate can either be altered on demand or preset to change at any time (e.g. during the night), and an onboard bolus calculator can advise the patient regarding the appropriate insulin dose at mealtime. Currently available pumps also have the capability for downloading data to a computer utilizing software designed to demonstrate glycemic patterns throughout the day and patient compliance with bolus injections [10] .
In patients with T1D, insulin pump therapy versus MDI provides improved glycemic control and stability without a concomitant increase in the rate of hypoglycemia [11] [12] [13] [14] [15] . The use of insulin pump in patients with T2D is a relatively recent practice and although the use of insulin pumps has been well documented in T1D [10] , relatively few randomized controlled studies including only small cohorts evaluating treatment with insulin pump in T2D have been published until 2014. In 2014 the OpT2mise study was published being the largest randomized controlled trial (RCT) to date of insulin pump therapy in patients with T2D [16] . It is estimated that there are 5.6 million insulin-treated diabetic individuals in the U.S., of whom 4.5 million have T2D. While 31% of patients with T1D use CSII only <5% of T2D patients use CSII. Notably, 71% of patients on MDI regimens report they do not regularly inject insulin outside the home, particularly those with T2D [17] . The use of CSII in patients with T2D has been endorsed by the American Diabetes Association as a feasible, although costly, alternative to basal-bolus therapy [18] . Training in the use of CSII should be delivered by a multidisciplinary team specialized in the care of patients with CSII which includes at least one physician, specialized nurse, and diabetes specialist dietician [19] .
We searched PubMed for reports published in English between 1990 and 1 March 2016. We used various combinations of the terms 'type 2 diabetes', 'pump', 'insulin pump therapy', 'continuous subcutaneous insulin infusion' and 'multiple daily injection therapy'. We identified uncontrolled studies and RCTs. We included in this narrative review studies with long-term as well as short-term CSII therapy in long-standing and newly diagnosed patients with T2D.
What's the evidence?
Long-term CSII therapy in patients with T2D
In recent years, patients with T2D who remained poorly controlled despite using multiple insulin injections were considered as candidates for CSII to improve their glucose control by providing a more physiological plasma insulin profile. Available data suggest that most demonstrated benefits of CSII observed in T1D patients probably apply to selected T2D patients as well. During recent years, we have been witness to stepwise progression of the data, starting with small uncontrolled studies and progressing to larger-scale controlled studies. In the earlier studies, the efficacy of CSII and MDI was often similar, while in studies from recent years superiority of CSII is observed. This difference may reflect the advancement in pump technology and the development of more user-friendly pumps. Table 1 reviews uncontrolled studies evaluating CSII therapy in patients with T2D [20] [21] [22] [23] [24] [25] [26] [27] . The various studies included up to 521 patients with long-standing diabetes formerly treated with oral hypoglycemics, basal insulin or basal-bolus insulin. The switch to CSII generally led to improved glycemic control, reduction in daily insulin dose and better patient satisfaction. The longest trial demonstrated sustained benefit of up to 6 years [21] . Studies were conducted in clinical research centres and hospitals as well as in small outpatient clinics [26, 27] .
RCTs evaluating the relative efficacy of CSII versus MDI have been published since the 1990s and are summarized in Table 2 [16, [28] [29] [30] [31] [32] [33] . Patients taking oral hypoglycemic agents or insulin at baseline were randomized to MDI or CSII for periods extending from 12 to 52 weeks. Some of the earlier trials failed to show benefit whereas the most recent OpT2mise trial which included a large heterogeneous population showed a significant benefit with regard to HbA 1c reduction, lower insulin requirement, and no significant change in weight or hypoglycemic events. This recently published study by Reznik et al. is a large-scale, multicentre RCT that compared the efficacy of CSII and MDI in patients with T2D who had previously been unable to reach HbA 1c targets despite using intensified MDI regimens [16] . In this study 331 patients with HbA 1c between 8% and 12% were randomized to pump therapy (n = 168) or MDI (n = 163) for 6 months. Pump treatment significantly improved glycemic control compared with MDI (mean difference between groups 0.7%). The reduction in HbA 1c levels observed in the pump therapy group was associated with a 20% decrease in the total daily insulin dosage compared with total daily insulin dosage in the MDI group and was not accompanied by an increase in hypoglycemia or weight gain. The investigators used a simple approach with few basal rates and fixed boluses, without the use of carbohydrate counting. The study population included patients with a wide age range (30-75 years) . A large percentage (38%) of participants had mild cognitive impairment. In the overall patient population, the decrease in HbA 1c was independent of diabetes duration, body-mass index, education level, Montreal Cognitive Assessment score, and number of blood glucose self-assessments done per day. In the OpT2mise study the investigators further evaluated the impact of insulin pump therapy on glycemic profiles using continuous glucose monitoring data collected over 6-day periods before and 6 months after randomization [34] . Compared with MDI, CSII treatment provided a significant improvement in glucose profile, with increased time spent within target ranges and less exposure to hyperglycemia, without increasing duration of hypoglycemia.
Short-term CSII therapy in patients with T2DM
Beta-cell dysfunction is associated with poor glycemic control in patients with T2DM, with glucotoxicity being a well-established reversible mediator of poor beta-cell function. Short-term CSII therapy aiming to attain normoglycemia and abate glucotoxicity was studied in newly diagnosed T2D patients and in patients with long standing disease.
Patients with newly diagnosed T2D
It had been hypothesized that intensive therapy in newly diagnosed patients could lead to long-term remission of the diabetes. In the Steno-2 study and UK Prospective Diabetes Study, patients exhibiting near-normal glycemic control at diagnosis of T2DM were reported to have a lower long-term cardiovascular mortality rate compared with patients with worse initial control [35, 36] . Aiming to attain normoglycemia close to disease onset has been studied with multiple treatment regimens including oral anti-diabetic drugs and insulin delivered as MDI or CSII. One of the justifications for early insulin treatment in patients with newly diagnosed T2D is the rapid reversal of glucolipotoxicity by insulin therapy [37] . Intensive therapy was delivered short term (2-3 weeks) with 3 to 24 months follow-up after termination of the intervention. The methodology as well as the primary endpoints differed in the various trials. Table 3 summarized the studies evaluating CSII therapy in patients with newly diagnosed T2D.
Ilkova et al. were the first to report the use of shortterm CSII in patients from Israel with newly diagnosed T2D in 1997 [38] . This small-uncontrolled study may be viewed as a feasibility test for the studies that followed.
Several studies were subsequently published in a Chinese population investigating the role of CSII in newly diagnosed patients. In these studies optimal glycemic control was achieved shortly after initiation of CSII therapy (within 6-7 days), while duration of the CSII therapy was 2 to 3 weeks.
A meta-analysis reviewing studies assessing short term insulin therapy (mainly CSII) in recently diagnosed patients with T2D concluded this treatment modality can lead to improvement in the underlying pathophysiology in early T2D mellitus, and might provide a treatment strategy for modifying the natural history of diabetes [39] . Short-term intensive insulin therapy has shown in Table 1 . Uncontrolled studies evaluating CSII therapy in patients with type 2 diabetes these trials an ability to improve β-cell function and reduce insulin resistance. The proposed mechanisms of remission induction by short term CSII include improvement in glucolipotoxicity, improved β-cell function possibly induction of better compliance: confrontation with intensive insulin therapy may possibly induce greater disease awareness and readiness to change in people diagnosed with an oftenasymptomatic disease than are oral agents. Based on these benefits, short-term intensive insulin therapy was recommended for selected patients with newly diagnosed T2D in the Chinese guidelines [40] . The main caveat in these trials is the absence of a long-term follow-up period; thus, the durability of the beneficial effect of short-term CSII on beta-cell function and glycemic control in T2DM patients remains to be defined.
Patients with long standing T2D Short-term intensive insulin therapy in long-standing diabetes as a means to improving glycemic control has been studied as well in a few studies: An early study published in 1988 assessed the impact of intensive insulin therapy delivered by CSII to 12 poorly controlled patients with long-standing T2D (duration 1-25 years). Short term induction of normoglycemia resulted in improved insulin secretion and beta cell function [41] . Park et al. [42] assessed long term glycemic remission, following CSII therapy in T2D Korean patients with long standing diabetes. The rate of remission was higher in patients with shorter diabetes duration, lower postprandial glucose levels, higher BMI and fewer and/or less severe complications. Limitations of this study included the absence of a control group and the ethnic homogeneity of the population.
A sensor augmented insulin pump (SAP) in patients with long-standing T2D (duration 3 -20 years) was evaluated in a six day intervention study of 60 patients, who had been taking four injections of insulin daily for more than 3 months with an HbA 1c level between 7.0% and 12.0% [43] . Patients were randomly assigned to CSII, MDI, or SAP. All had good cognitive and motor abilities and were willing to be randomized to either treatment arm. Patients in the SAP arm monitored the glucose values and trends throughout the trial period, and notified the study physician of any high glucose or trend, who in turn adjusted their insulin levels during day and night. SAP therapy was superior to CSII and to MDI in attainment of lower glucose levels, lower rates of hypoglycemia, and reduction in blood glucose fluctuations. This small trial indicates that for select patients with T2D who appropriately respond to the cues provided by the glucose sensor, with the assistance of a physician, improved glycemic control may be rapidly attained. Finally, a recent RCT which included 150 subjects with long-standing T2D (9 ± 2.5 years) and elevated HbA 1c levels (11 ± 1.2%) randomly allocated patients to various regimens of insulin therapy (MDI, mix insulin, or CSII) for 3 months [44] . CSII therapy was associated with markedly lower doses of total daily insulin, increase in fasting insulin secretion after termination of the intervention, and better reduction of HbA 1c level compared to the other insulin regimens. The rates of hypoglycemic episodes were lower in the CSII group compared to the other groups.
We conclude that short-term CSII therapy aiming for normoglycemia exerted a positive effect on diabetes remission, glycemic control, and improved insulin resistance and beta-cell function in the majority of the patients both when delivered at diagnosis and when delivered to individuals with long-standing disease. Before considering this intervention as a routine approach more controlled studies are needed, including heterogonous patient populations and with longer follow-up.
The effects of CSII therapy combined with glucose lowering agents
Combination of insulin treatment with insulin sensitizers or with incretin-based treatments might enable attainment of similar, or possibly better, glycemic goals than insulin treatment alone, but with lower insulin needs, less [75] 118 Uncontrolled study 2-3 weeks 1 year 55 Self-care adherence and higher HOMA-IR at baseline were independent predictors for remaining in remission. Liu (2015) [76] 104 CSII treated subjects 2 weeks 1 year 52 A steady decline in total daily insulin during the period of CSII therapy was associated with long-term remission.
weight gain, and less hypoglycemia [45] . Several studies have assessed the benefits obtained with the combination of CSII and glucose lowering agents in patients with T2D. Combination of sitagliptin with CSII for 2 weeks enabled attainment of similar glycemic targets versus CSII alone, but with lower glycemic variability and improved beta cell function [46, 47] . A study which randomized poorly controlled patients to CSII alone or CSII with the combination of exenatide for 3 days demonstrated increased glycemic variability with exenatide but reduced glucose AUC in an OGTT [48] . A study assessing the benefit of the addition of liraglutide therapy to CSII versus CSII alone demonstrated faster attainment of euglycemia with liraglutide and improved beta-cell function over 12 weeks of therapy. Glycemic variability was not reported in this study [49] . Longer and larger trials may be needed to fully demonstrate the effect of the combination of various antidiabetic drugs with CSII in patients with T2D and its' possible contribution to reducing glycemic variability, improving beta cell function, and better and faster attainment of glycemic targets.
Glucose variability and CSII treatment
CSII demonstrated lower glucose variability versus MDI in patients with T1D and good metabolic control (HbA 1c <7.5%), yet the advantage disappeared with deterioration of glycemic control [50, 51] . Studies of CSII in patients with T2D did not consistently demonstrate reduced glucose variability with CSII. Treatment with CSII in the OpT2mise study resulted in less time spent in hyperglycemia (glucose >180 mg/dl and glucose >250 mg/dl) versus MDI, yet glucose variability improved by a similar extent in both groups at 6 months [34] . Furthermore, in a trial of elderly patients with T2D, glucose variability improved equally with CSII and MDI treatment [52] . It is possible that the poorer glycemic control of the OpT2mise population, or the lower glycemic variability in insulin-treated patients with T2D versus T1D accounted for the lack of improved glycemic variability with CSII observed in these trials.
Potential barriers to CSII therapy in patients with T2D
CSII has shown marked benefits in the previously discussed trials extending throughout the spectrum of patients. It has been used as a mean to reduce glucotoxicity in the short term and induce glycemic remission in newly diagnosed patients, and has shown benefit in poorly controlled patients with long-standing disease. However, multiple aspects of care need to be considered with respect to widespread use of CSII.
Satisfaction and quality of life (QOL)
Assessment of quality of life (QOL) and satisfaction in people with diabetes is increasingly seen as an important aspect of care, particularly as new treatments and services are introduced that may be more demanding on the one hand but offer improved metabolic control on the other [53] . Treatment satisfaction and QOL are important because of their association with treatment preference, adherence to treatment, and better glycemic control [49] . Few studies assessed different aspects of satisfaction and QOL measures using various means. In a multicentre randomized 24-week trial in 132 CSII naïve patients with T2D, Raskin et al. studied patient satisfaction scores for convenience, flexibility, ease of use, and overall preference [29] . Overall satisfaction was significantly higher with CSII than with MDI. Ninety-three percent of patients using CSII preferred the pump to their previous injectable insulin regimen. [23] . In a study from the USA, Gentry et al. evaluated patient satisfaction after changing from MDI to CSII therapy in patients with T2D from a private physician's clinic (n = 30). Ninety-five percent of patients preferred CSII therapy to previous injection regimen for various reasons [26] . Patients who utilized CSII thought that the treatment was more convenient, less burdensome, and provided better control of fluctuations in blood glucose. Edelman et al. also showed that overall treatment preference and treatment satisfaction improved significantly with CSII therapy [22] . Herman et al. and Berthe et al. showed that patient's satisfaction was comparable with both intensive treatments [30, 32] . In a small cross-over study from France (n = 17), the authors reported that both groups of patients (MDI and SCII treated) were satisfied with their insulin regimens, with a slight preference toward the MDI regimen compared to CSII (NS). When asked to choose at the end of the study, ten patients chose CSII while seven chose MDI [55] .
In conclusion, in most studies, treatment satisfaction and QOL in patients with T2D were higher with CSII than with MDI; therefore improving satisfaction from therapy and QOL should be among the goals when considering CSII therapy in patients with T2D.
Age of patients
Patients with T2D are often more elderly than those with T1DM and may suffer of multiple comorbidities, such as decreased dexterous abilities, impaired eyesight, and cognitive impairment. The studies described included patients within a wide range of ages from 30 to 75-year-old patients. One hundred seven patients with T2D age ≥60 years were prospectively randomized to CSII versus MDI for 12 months [30] . Both modalities achieved excellent glycemic control with good safety and patient satisfaction. Yeoh et al. retrospectively reviewed the charts of all patients started on CSII over the past 12 years in their treatment facility [56] . Of the 360 patients included, 34 (9.4%) were ≥60 years of age, the majority (31/34) being patients with T1D. Improvement in glycemic control in the elderly was similar to that observed in the entire cohort. We conclude that in otherwise appropriate insulin pump candidates, advanced age should not deter from considering this form of therapy.
Weight gain
Fear of weight gain is often voiced as a caveat to initiation of pump therapy, with concern that the increased availability of insulin may lead the patients to inject more prandial insulin, eat more and gain more weight. However, in the clinical trials, pump treatment was not associated with clinically significant weight gain: in several studies no weight gain was observed [16, 20, 31, 32, 57] whereas in others only a minimal weight gain of 1 -2 kg was noted [22, 29, 30] .
In conclusion, CSII therapy is not associated with clinically significant weight gain in patients with T2D.
Lack of autonomy and impaired cognitive status
Pump therapy is generally perceived as requiring a high level of technical skill and learning ability on the part of the patient. Executive functioning and speed may be impaired in older patients with T2D in comparison with their healthy counterparts [58] . The patient's ability to manage a CSII device was evaluated in very few studies. Reznik et al. examined the patient's ability to manage CSII: 33.3% had complete autonomy, 41.7% had technical autonomy, and 25% remained dependent on aid from a nurse. Patients with complete autonomy or on the contrary patients managed by a nurse showed a greater improvement of their glycemic control than those with technical autonomy only [21] . In a later study by the same group the authors evaluated tools that may help determine the ability of patients with T2D to autonomously manage a pump device [59] . They concluded that cognitive and mood evaluation tools such as the Montreal Cognitive Assessment and the Hospital Anxiety and Depression Scale may be helpful for detecting cognitive and operative disabilities and therefore identify patients who may benefit from personalized training programmes or alternatively a nurse's assistance for the safe utilization of CSII devices [59] . They observed that in a group of patients, who were initially trained to pump utilization during a standardized 5-day session, half of patients were not completely autonomous at discharge but 77% reached complete autonomy after 1 year of pump utilization and 23% remained partially or completely dependent on a nurse's assistance. In the OpT2mise study [16] 38% of patients in the pump treatment group had mild cognitive impairment yet still benefited from its use suggesting that pump treatment can be used effectively by such patients. Successful CSII utilization depends on a patient's ability to engage the device effectively and consistently, and this process may be limited by unrecognized cognitive and/or operative disabilities.
Hypoglycemic episodes
Hypoglycemia is the main barrier to effective glucose lowering in patients with diabetes. A meta-analysis of randomized controlled trials of MDI versus CSII indicated there was no significant difference between the two modalities in the rates of severe hypoglycemia, nocturnal hypoglycemia, and minor hypoglycemia [12] . Generally, severe hypoglycemic episodes were very infrequent in all reviewed studies. Continuous glucose monitoring is a valuable tool to assess time spend in hypoglycemia. In a study by Li et al. blood glucose fluctuations were compared between three groups of interventions: CSII, MDI with mixed insulin preparation thrice daily, and MDI with glargine plus three injections of short acting insulin [60] . There was no difference in the time spent in the hypoglycemic range between the different methods of intensive insulin treatment. Important information was provided by data from the OpT2mise study; blinded CGM data were available for patients treated by CSII and MDI. Although a reduction in exposure to hyperglycemia in the CSII group was demonstrated, it was not associated with an increase in time spent in the hypoglycemic range (glucose levels < 70 mg/dL) [34] . CSII treatment is not associated with elevated risk for hypoglycemic episodes. Therefore, we conclude that this factor should not be a barrier while considering various options of intensive insulin treatments.
Complexity of using CSII
In T1D patients, there is a need for accurately configuring bolus by carbohydrate content and pre-meal glucose levels adjustment. Multiple basal rates are frequently used in these patients. Engaging basal-bolus method in T2D can be a barrier for patients and their physicians as well. The carbohydrates counting method is less important in patients with T2D. Bergenstal et al. showed that a simple dosing regimen of fixed mealtime boluses for T2D patients treated with MDI-with no carbohydrate counting-allows for glycemic control comparable to that achieved with a more elaborate regimen [61] . In the Opt2mise study [16] patients in the pump treatment group had access to the pump bolus calculator and used it inconsistently, with 93 (59%) of 158 patients using it less than 25% of the time. Use of the bolus calculator was not associated with a reduction of HbA 1c . The focus of the study by Edelman et al. was to better understand insulin doses and dosing patterns necessary to achieve optimal glycemic control with insulin pump therapy [22] . The vast majority of patients were able to achieve good glycemic control with one or two daily basal rates. From an HbA 1c -lowering perspective, there did not appear to be an advantage to using more than one or two basal rates. Cohen et al. assessed the convenience and physician's satisfaction of implementing of a simple insulin dosing protocol in patients with T2D switched from MDI to CSII treatment [62] . They found that the protocol was more efficient, time saving, and structured compared to the commonly used process. Apparently, the insulin regimen used can be simpler in patients with T2D compared to T1D patients, using fewer basal rates and possibly fixed boluses with less of a need for carbohydrate counting.
Cost
As the prevalence of diabetes increases around the world, managing the costs associated with treating the disease and its complications is a vexing issue. A major component of diabetes care expenditure is insulin. Only few countries reimburse insulin pump therapy in patients with T2DM [63] .
David et al. examined the financial impact of switching from MDI therapy to CSII therapy on the cost of insulin and other anti-diabetes medication in individuals with T2DM [64] . Patient-level data were extracted from two big databases covering over 5 million patients.
Expenditures including insulin and anti-diabetic medications were compared between a group of MDI treated patients (n = 6553) and a group of patients who switched MDI therapy to CSII (n = 181). This analysis suggests that CSII therapy in patients with T2DM may help reduce of the dose requirement of insulin, as evidenced by the reduction in insulin expenditures among patients with T2DM who switch from MDI therapy to CSII pump therapy. In this analysis insulin supplies expenditures were not included limiting the conclusions which may be drawn from this data.
A retrospective study conducted in the USA by Medtronic Inc. over a 4-year period analysed a large sample of managed care enrollees with T2D patients after switching from MDI to CSII [65] . After initiation of pump therapy, anti-diabetic drug utilization was reduced by 0.67 drug (a change of 46%), and more than one-third of subjects discontinued anti-diabetic drugs altogether. Inpatient admissions and emergency department visits decreased significantly yet ambulatory visits significantly increased.
Cost-benefit analyses of CSII in people with T1D have concluded that CSII is cost-effective when taking into account the likelihood of improving glycemic control and its benefit in reducing the risk of long term complications [66, 67] . These conclusions might also be applicable for people with T2DM.
Why might CSII work better than MDI injections in T2DM?
1 Predictable absorption of basal insulin: the large-dose and therefore large volume of injected, long-action insulin that is required in insulin-resistant patients receiving MDI injections is more poorly and inconsistently absorbed compared to the small-volume basal rate administered by CSII. It has been shown that the same dose of insulin delivered by CSII at the basal rate versus an injection of long-acting insulin glargine achieved better glycemic control and higher circulating insulin levels with less fluctuation [68] . Thus, the glycemic advantage of pump treatment probably relies mainly on better delivery of the basal component of insulin infusion. 2 Better treatment satisfaction: treatment satisfaction in patients with T2DM is higher with CSII than with MDI injections, suggesting that adherence to treatment might be increased in those receiving pump therapy [29] . Pump treatment might be more convenient for patients, lessening the burden associated with dose tracking and scheduling, and improving adherence to insulin injections. Limitations of studies examining the efficacy of insulin pump therapy in patients with T2d
1 CSII is generally offered to patients requiring multiple injection or high doses of insulin therapy. This needs to be weighed against new treatment options for patients with significant insulin resistance such as bariatric surgery, GLP-1 analogs, new short and long-acting insulin analogs and sodium glucose co-transporter 2 inhibitors. 2 Many of the studies with CSII have been conducted in the Far East (Korea, China). Asian subjects with T2D are typically less overweight than Western patients with T2D, beta-cell dysfunction is more prominent and there are cultural or ethnic factors that make the generalization of these studies to Western population problematic. 3 The relative efficacy and safety of CSII versus MDI in patients with tight glycemic control and patients with a history of recurrent or severe hypoglycemia and hypoglycemia unawareness remain unclear.
Conclusion
Insulin pump therapy is a proven treatment of preference for patients with T1D because of its ability to closely mimic physiological insulin secretion. Studies comparing MDI and CSII favour the latter based on HbA 1c reduction, fewer episodes of hypoglycemia, and reduced glycemic variability evidenced by a continuous glucose monitoring system [10] . Additionally, studies have shown that patients with T1D prefer pump therapy to injection therapy and that it improves quality of life [71] . Fewer studies investigate CSII in patients with T2D but it seems that many of these findings may be applicable to patients with T2D as well. Pros and cons of CSII compared to MDI are summarized in Box 1. Although MDI therapy is widely regarded as the 'last step' in insulin intensification for patients with T2DM [2,3], many patients on this regimen are unable to achieve or maintain adequate glycemic control [4 ] .This highlights the importance of assessing alternative therapeutic modalities-including insulin pump therapy-for this patient population. Based on available studies, selected and motivated T2D patients uncontrolled on MDI who are capable of managing a technical device might benefit from CSII. Current policies regarding CSII use in patients with T2D and assessment of cost-benefit ratio need to be evaluated.
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